Endoscopic Retrograde Cholangiopancreatography

Endoscopic Retrograde Cholangiopancreatography Patient Registry

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.

Study Overview

• Status: Recruiting
• Conditions: Gastro-Intestinal Disorder
• Intervention / Treatment: Other: Patients undergoing ERCPs at Methodist Dallas Medical Center

Detailed Description

The primary objective of this study is to provide a mechanism to store the following information about patients undergoing ERCPs at Methodist Dallas Medical Center. This registry will be permissive of quality improvement and research studies.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Crystee Cooper, DHEd; Phone Number: 214-947-1280; Email: ClinicalResearch@mhd.com
• Study Contact Backup: Name: Kavya Mankulangara; Phone Number: 214-947-4604; Email: ClinicalResearch@mhd.com

Study Locations

• United States
  • Texas
    • Dallas, Texas, United States, 75203
      • Recruiting
      • Methodist Dallas Medical Center- Clinical Research Institute
      • Contact: Kavya Mankulangara; Phone Number: 214-947-4604; Email: ClinicalResearch@mhd.com
      • Contact: Colette Ngo Ndjom; Phone Number: 214-947-1289; Email: ClinicalResearch@mhd.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients who underwent ERCP and in MDI(Methodist Digestive Institute) registry.

Description

Inclusion Criteria:

Patients >15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025

Exclusion Criteria:

Patients <15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Underwent ERCP; Underwent ERCP between January 1, 2000 through December 31, 2025	Other: Patients undergoing ERCPs at Methodist Dallas Medical Center; The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Underwent ERCP	Patients undergoing ERCPs at Methodist Dallas Medical Center.	25 years

Collaborators and Investigators

• Sponsor: Methodist Health System
• Investigators: Principal Investigator: Prashant Kedia, MD, Methodist Health System

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): February 1, 2028

Study Registration Dates

• First Submitted: March 18, 2026
• First Submitted That Met QC Criteria: March 18, 2026
• First Posted (Actual): March 24, 2026

Study Record Updates

• Last Update Posted (Actual): March 24, 2026
• Last Update Submitted That Met QC Criteria: March 18, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases
• Other Study ID Numbers: 046.GID.2024.D

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The investigator will make all possible efforts to ensure compliance with all policies regarding sharing of Protected Health Information or research information. Only de-identified Protected Health Information will be shared in relevant research mediums.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No